Long-Acting, Self-Administered HIV Therapy with the CCR5 Antibody PRO 140 ("NIAID Study")

Trial Profile

Long-Acting, Self-Administered HIV Therapy with the CCR5 Antibody PRO 140 ("NIAID Study")

Planning
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2013

At a glance

  • Drugs PRO 140 (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms NIAID
  • Most Recent Events

    • 29 Apr 2013 After a 3-year delay, an agreement has been reached with Ajinomoto Althea, a fill and finish plan has been put in place, and enrolment is expected to start in the fourth quarter of 2013, according to a CytoDyn media release.
    • 06 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top